Intercept Pharmaceuticals Notches Convincing Q2 Beats
Intercept Pharmaceuticals (NASDAQ: ICPT) isn't exactly having a summer to remember, but the second-quarter results it delivered early Monday were quite encouraging.
For the period, the company's total revenue came in at $77.2 million, up 16% year over year. Its net loss narrowed over that stretch of time to $63.3 million ($1.92 per share) from its Q2 2019 deficit of $71.4 million.
On average, analysts had estimated Intercept would book just under $72.2 million in revenue, and suffer a $2.92 per share bottom-line loss.
Source Fool.com
